Implementation of a Three-Way Comparability Assessment for a Bioanalytical Anti-Drug Antibody Method-Reference-Cited by-同舟云学术

Implementation of a Three-Way Comparability Assessment for a Bioanalytical Anti-Drug Antibody Method

Published:2024-04-18 Issue:3 Volume:26 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Kwok Rosanna S.,Nijem Ihsan,Brady Ann,Hendricks Robert

Abstract

AbstractImmunogenicity evaluation is a critical part of drug development. Regulatory guidelines from multiple health agencies provide recommendations for the development and validation of anti-drug antibody (ADA) assays to assess immunogenicity in clinical trials. These recommendations primarily describe an ADA method run in one bioanalytical laboratory supporting a biotherapeutic molecule; however, there are increasing instances that may necessitate the support of the ADA method being run in more than one laboratory. A program can rapidly expand into multiple clinical studies within one or multiple countries, where the most appropriate way to support the program is by having multiple laboratories perform ADA sample analysis. In addition, there may be certain country-specific challenges that may make it infeasible to transport samples outside of the country for analysis. China for example has a lengthy sample exportation process that has potential to negatively impact study timelines. If multiple laboratories analyze samples using the same ADA method, comparable method performance should be established. Here, we describe a three-way assessment of ADA assay comparability between two US-based bioanalytical laboratories and one based in China. Graphical Abstract

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1208/s12248-024-00917-7.pdf

Reference15 articles.

1. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3(4):349–60. https://doi.org/10.2174/1389201023378175.

2. U.S. Food and Drug Administration. Guidance for industry: immunogenicity testing of therapeutic protein products — developing and validating assays for anti-drug antibody detection. February 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug. Accessed 13 May 2023.

3. National Medical Products Administration. Technical guidance for immunogenicity studies of drugs. March 2021. https://www.cde.org.cn/main/att/download/7d89a3b3b078e2682e935bd5d85ce7a8. Accessed 13 May 2023.

4. European Medicines Agency. Immunogenicity assessment of biotechnology-derived therapeutic proteins—– scientific guideline EMEA/CHMP/BMWP/14327/2006. May 2017. https://www.ema.europa.eu/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 13 May 2023.

5. Tatarewicz S, Moxness M, Weeraratne D, Zhou L, Hale M, Swanson SJ, et al. A step-wise approach for transfer of immunogenicity assays during clinical drug development. AAPS J. 2009;11(3):526–34. https://doi.org/10.1208/s12248-009-9130-3.